Acadia Pharmaceuticals Secures Patent Protection For NUPLAZID
$ACAD
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) has recently achieved a significant victory that underscores its commitment to securing and extending its intellectual property rights, particularly for its flagship product, NUPLAZID (pimavanserin), which is used in the treatment of Parkinson’s Disease Psychosis. This development follows a favorable ruling from the US District Court for the District of Delaware, which found that Aurobindo Pharma Limited infringed on specific claims of Acadia’s ‘721 formulation patent.
The court’s decision not only reaffirms the validity of Acadia’s claims against Aurobindo but also extends the patent protection of NUPLAZID until 2038.
This extension is pivotal for Acadia as it ensures long-term commercial exclusivity of NUPLAZID, thereby potentially enhancing the stability and sustainability of the company’s market position.
“We are very pleased with today’s decisive ruling in our favor, which provides patent protection for NUPLAZID 34 mg capsule formulation into 2038,” said Catherine Owen Adams, Chief Executive Officer. “This result highlights Acadia’s dedication to safeguarding our advancements in therapies for conditions with significant unmet medical needs.”.
Acadia has outlined plans for its upcoming research and development day on June 25, where it expects to showcase its latest scientific advancements and strategic initiatives. This event is anticipated to be a significant milestone for the company, providing insights into its future direction and ongoing projects. The implications of the recent court ruling and Acadia’s robust pipeline are profound, not only for the company but also for the broader neuroscience and pharmaceutical industries.
Actively advancing its research and development pipeline, the company is not only focused on enhancing NUPLAZID but is also developing treatments for other neurological and rare diseases, including Rett syndrome and Alzheimer’s disease psychosis. This diverse clinical-stage pipeline underscores Acadia’s commitment to addressing the broad spectrum of neurological disorders, further solidifying its role as a leader in neuroscience innovation.
**DISCLAIMER: THIS CONTENT IS FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE INTERPRETED AS INVESTMENT ADVICE. INVESTING INVOLVES RISK, INCLUDING THE POTENTIAL LOSS OF PRINCIPAL. READERS ARE ENCOURAGED TO CONDUCT THEIR OWN RESEARCH AND CONSULT WITH A QUALIFIED FINANCIAL ADVISOR BEFORE MAKING ANY INVESTMENT DECISIONS.**